吴凯珊,伍俊妍,张俊州,周满如
WU Kaishan,WU Junyan,ZHANG Junzhou,ZHOU Manru

• 1:中山大学孙逸仙纪念医院
• 2:广东医学院

摘要(Abstract)：

目的分析治疗系统性红斑狼疮处方超说明书用药的合理性。方法选取本院2014-01~12治疗多囊卵巢综合征的门诊处方7 535张进行处方分析,通过查阅国外说明书、国内外指南、MICROMEDEX Health Care Series数据库、国内外文献等方式对该超说明书用法进行合理性评价。结果超说明书用药药物包括地塞米松、复方环磷酰胺片、吗替麦考酚酯胶囊/片、甲氨蝶呤片/针剂、他克莫司、沙利度胺片,超说明书处方所占处方比例为:39.06%。地塞米松、复方环磷酰胺片、吗替麦考酚酯胶囊/片、甲氨蝶呤片/针剂、他克莫司、沙利度胺片超说明书用药均有国内外指南推荐,有较好的询证医学证据级别。结论所评价处方的超说明书用药有指南推荐或有合理的医学实践证据,患者用药有指征,处方合理。
OBJECTIVE To analyze the rationality of off-label drug use in prescriptions in the treatment of systemic lupus erythematosus. METHODS A total of 7 535 outpatient prescriptions in the treatment of systemic lupus erythematosus selected from January to December 2014 in the hospital were analyzed. Rationality of the off-label drug use was evaluated by searching foreign package inserts,guidelines at home and abroad,MICROMEDEX Health Care Series database,domestic and foreign literatures and so on.RESULTS Drugs with off-label use included dexamethasone,cyclophosphamide,mycophenolate mofetil,methotrexate,tacrolimus and thalidomide tablets. 39. 06% of prescriptions involved in off-label drug use. Conclusion The off-label use in metformin,spironolactone and letrozole were recommended by domestic and overseas guidelines,with better level of evidence of evidence-based medicines. CONCLUSION The evaluated off-label drug use in prescriptions were recommended by guidelines or with rational evidence of medical practice. The drug applications in patients were according to indications,the prescriptions were reasonable.

关键词(KeyWords)： 系统性红斑狼疮;超说明书用药;分析
systemic lupus erythematosus;off-label drug use;analysis

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 吴凯珊,伍俊妍,张俊州,周满如
WU Kaishan,WU Junyan,ZHANG Junzhou,ZHOU Manru

参考文献(References)：

• [1]孙广超,曾华松.系统性红斑狼疮合并感染研究进展[J].中国实用儿科杂志,2015,30(1):21-24.
• [2]邱凯锋,林茵.系统性红斑狼疮的临床用药进展[J].中国药房,2006,17(14):1108-1109.
• [3]卢传坚主编.常见皮肤病性病现代治疗学[M].1版.北京:学苑出版社,2000:5581.
• [4]李明.红斑狼疮的临床用药[J].世界临床药物,2003,24(8):4671.
• [5]张增珠,魏筱华,陈集志.临床药师对1例系统性红斑狼疮致多脏器受累患者的药学监护[J].中国药房,2013,24(34):3258-3259.
• [6]费允生,甘凤英,侯勇.近25年系统性红斑狼疮的死因构成回顾性研究[J].中华风湿病学杂志,2012,16(9):596-600.
• [7]Mok M,Wong S,Chan T,et al.Non-tuberculous mycobacterial infection in patients with systemic lupus erythematosus[J].Rheumatology,2007,46(2):280.
• [8]Chen H,Tsai WP,Leu HS,et al.Invasive fungal infection in systemic lupus erythematosus:an analysis of 15 cases and a literaturreview[J].Rheumatology,2007,46(3):539.
• [9]伍俊妍,李磊,李国成,等.治疗多囊卵巢综合征处方的超药品说明书用药析[J].中国药房,2014,25(34):3203-3204.
• [10]葛饮南,邵蓉,谢金平.医院“超说明书用药”管理与应对流程初探[J].中国药事.2013,27(5):544.
• [11]杨丽杰,李希妍,张郝程,等.我国临床超说明书用药现状和风险防范建议[J].中国药房,2014,25(42):4006-4009.
• [12]张波,郑志华,李大魁.超药品说明书用药参考[M].1版,北京:人民卫生出版社,2013:9-13.
• [13]中华医学会.临床诊疗指南.风湿病分册[M].7版,北京:人民卫生出版社,2007:53-55.
• [14]游运辉,赵洪军,罗卉,等.地塞米松短期静脉滴注治疗活动性系统性红斑狼疮的临床观察[J].中国医学工程,2007,15(10):853-854.
• [15]林顺平,林淑屏,石艳清.甲氨蝶呤治疗系统性红斑狼疮临床研究[J].医师进修杂志(内科版),2004,27(6):32-33.
• [16]李群苑,张科,劳敏曦.甲氨蝶呤治疗系统性红斑狼疮的临床疗效及安全性分析[J].吉林医学,2014.35(13):272-2765.
• [17]曾昭球.小剂量环磷酰胺联合免疫吸附治疗系统性红斑狼疮的效果观察[J].临床医学工程,2013,20(4):450-451.
• [18]岳辉,孟璐,卓媛,等.环磷酰胺冲击治疗系统性红斑狼疮60例临床护理[J].齐鲁护理杂志,2012,18(36):70-71.
• [19]李倩倩,姜振宇,赵令.吗替麦考酚酯对老年系统性红斑狼疮患者免疫细胞水平变化的影响[J].中国免疫学杂志,2012,28(12):1136-1138.
• [20]林言华.吗替麦考酚酯联合糖皮质激素治疗系统性红斑狼疮的临床疗效观察[J].亚太传统医药,2012,8(10):160-161.
• [21]Novak N,Kwiek B,Bieber T.The mode of topical immunomodulators in the immunological network of atopic dermatitis[J].Clin Exp Dermatol,2005,30(1):160-164.
• [22]何迅,段西凌,陈学军,等.他克莫司软膏治疗系统性红斑狼疮面部皮损疗效观察[J].中国皮肤性病学杂志,200,22(8):472-473.
• [23]房蔚霞,郑文静,卢月珍.急诊病人家属院外急救知识调查分析[J].护理学杂志,2006,21(3):64-65.
• [24]吴鸥,冯玫,陈立红.他克莫司治疗系统性红斑狼疮皮肤损害病人的护理[J].护理研究,2009,23(1):183-184.
• [25]王文琴.沙利度胺治疗系统性红斑狼疮皮肤黏膜损害疗效观察[J].浙江中西医结合杂志,2010,20(12):748-750.